FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Reiterates Buy Opinion On Shares Of Citigroup Inc.

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our target price by $10 to $150 applying a forward P/E of 13.2x that is near the midpoint of the historical averages for three years at 15.1x and five years at 11.9x on forward normalized earnings. We are confident C is well positioned to accelerate growth and performance. Looking ahead for 2026, we believe there is ample market opportunity to exceed consensus expectations on revenue growth and wider margins for all businesses. We are increasing our 2026 EPS estimate by $1.55 to $11.30 and 2027's by $0.80 to $12.50 on projected revenue of $93.5B (prior $88.3B) and $98.5B ($92.0B). We moved to a new valuation level on price to NTBV at a premium of 1.5x, which is still below direct peers trading anywhere from 1.7x to 2.5x. We see upside to our target based on C's leading position in treasury securities services and its position as one of the top-five players in investment banking. Valuation risk may rest with a change in macroeconomic conditions outside the U.S., where C has more exposure than peers.

Related Articles

Asia

Beijing Enlight Media Q1 Profit Falls 99%; Shares Down 8%

Beijing Enlight Media Co (SHE:300251) posted first-quarter attributable net profit of 23.3 million yuan, down 99% from 2.02 billion yuan the previous year.Earnings per share went down to 0.01 yuan from 0.69 yuan, according to a Wednesday filing with the Shenzhen bourse.Operating revenue fell 94% year over year to 190.6 million yuan from 2.97 billion yuan.Shares of the media company were down 8% in recent trade.

$SHE:300251
Asia

Enlight Media 2025 Profit Jumps 473%; Shares Fall 7%

Beijing Enlight Media (SHE:300251) posted 2025 attributable net profit of 1.67 billion yuan, up 473% from 292.0 million yuan the previous year.Earnings per share went up to 0.57 yuan from 0.10 yuan, according to a Wednesday filing with the Shenzhen bourse.Operating revenue jumped 155% year over year to 4.04 billion yuan from 1.59 billion yuan.Shares of the media company were down 7% in recent trade.

$SHE:300251
Asia

CR Double-Crane Pharma Gets Nod to Name Unit as Marketer of Endometriosis Drug

China Resources Double-Crane Pharmaceutical (SHA:600062) received approval from the National Medical Products Administration to change the marketing authorization holder of dienogest tablets, according to a Shanghai bourse filing on Wednesday.Under the approved supplementary application, the pharmaceutical company's subsidiary, CR Zizhu Pharmaceutical, becomes the marketing authorization holder, as well as the manufacturer of the endometriosis drug.

$SHA:600062